Barclays’s Exact Sciences EXAS Stock Holding History

Barclays’s Portfolio EXAS Stock Details EXAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-47,400	Closed	-$2.66M	–	5349
2024 Q4	$2.66M	Buy	47,400 +45,400	+2,270%	+$2.83M	﹤0.01%	2680
2024 Q3	$136K	Sell	2,000 -68,000	-97%	-$3.84M	﹤0.01%	4485
2024 Q2	$2.96M	Sell	70,000 -47,500	-40%	-$2.61M	﹤0.01%	1864
2024 Q1	$8.11M	Buy	+117,500	New	+$7.43M	﹤0.01%	1542
2021 Q1	–	Sell	-23,400	Closed	-$3.1M	–	4842
2020 Q4	$3.1M	Buy	23,400 +17,100	+271%	+$2.07M	﹤0.01%	1882
2020 Q3	$642K	Hold	6,300	–	–	﹤0.01%	3038
2020 Q2	$548K	Sell	6,300 -165,000	-96%	-$13.2M	﹤0.01%	3271
2020 Q1	$9.94M	Sell	171,300 -9,500	-5%	-$771K	0.01%	987
2019 Q4	$16.7M	Buy	180,800 +82,700	+84%	+$7.27M	0.01%	1053
2019 Q3	$8.87M	Buy	98,100 +33,900	+53%	+$3.86M	0.01%	1378
2019 Q2	$7.58M	Sell	64,200 -7,600	-11%	-$766K	﹤0.01%	1535
2019 Q1	$6.22M	Sell	71,800 -124,000	-63%	-$10.6M	﹤0.01%	1507
2018 Q4	$12.4M	Buy	195,800 +74,600	+62%	+$5.12M	0.01%	1031
2018 Q3	$9.56M	Sell	121,200 -38,600	-24%	-$2.52M	0.01%	1290
2018 Q2	$9.55M	Buy	159,800 +54,200	+51%	+$2.92M	0.01%	1257
2018 Q1	$4.26M	Buy	105,600 +22,800	+28%	+$1.11M	﹤0.01%	1772
2017 Q4	$4.35M	Sell	82,800 -115,700	-58%	-$6.18M	﹤0.01%	1772
2017 Q3	$9.35M	Buy	198,500 +51,400	+35%	+$2.07M	0.01%	1092
2017 Q2	$5.2M	Buy	147,100 +76,100	+107%	+$2.35M	0.01%	1443
2017 Q1	$1.68M	Buy	71,000 +6,300	+10%	+$125K	﹤0.01%	2264
2016 Q4	$864K	Sell	64,700 -219,800	-77%	-$3.55M	﹤0.01%	2893
2016 Q3	$5.28M	Buy	284,500 +34,600	+14%	+$610K	0.01%	1246
2016 Q2	$3.06M	Buy	249,900 +231,500	+1,258%	+$1.74M	﹤0.01%	1673
2016 Q1	$110K	Sell	18,400 -104,100	-85%	-$666K	﹤0.01%	4283
2015 Q4	$1.1M	Buy	122,500 +82,900	+209%	+$771K	﹤0.01%	2529
2015 Q3	$673K	Sell	39,600 -143,500	-78%	-$3.3M	﹤0.01%	3085
2015 Q2	$5.31M	Sell	183,100 -107,300	-37%	-$2.7M	0.01%	1449
2015 Q1	$6.39M	Sell	290,400 -86,500	-23%	-$2.19M	0.01%	1377
2014 Q4	$10.2M	Buy	376,900 +322,100	+588%	+$7.84M	0.01%	1175
2014 Q3	$1.04M	Sell	54,800 -591,000	-92%	-$10.8M	﹤0.01%	3310
2014 Q2	$11M	Buy	645,800 +7,900	+1%	+$109K	0.01%	1086
2014 Q1	$8.93M	Buy	637,900 +607,700	+2,012%	+$8.21M	0.01%	1229
2013 Q4	$332K	Sell	30,200 -7,700	-20%	-$88.3K	﹤0.01%	4493
2013 Q3	$417K	Sell	37,900 -40,100	-51%	-$515K	﹤0.01%	4311
2013 Q2	$1.08M	Buy	+78,000	New	+$847K	﹤0.01%	3250

Other funds holding EXAS

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

PRS

Pinkerton Retirement Specialists Coeur D Alene, Idaho $1.16B AUM 28.78% 1-Year Est. Return

PWMAG

Pinnacle Wealth Management Advisory Group Red Bank, New Jersey $1.46B AUM 22.77% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Broadwater Capital Boston, Massachusetts $138M AUM 28.86% 1-Year Est. Return

Barclays's EXAS Position: Q1 2026 in Review

Barclays sold out of Exact Sciences (EXAS) in Q1 2026, closing a stake of 191,743 shares — an estimated $19.5M sold.

Barclays first reported a position in EXAS in Q2 2013 and held it in 51 quarters. The position peaked at $23.7M in Q2 2025. 7 funds tracked by Wall St. Rank hold EXAS as of Q1 2026.

Barclays reported no remaining Exact Sciences position as of Q1 2026 after selling out during the quarter.
Barclays sold 191,743 Exact Sciences shares in Q1 2026, an estimated $19.5M.
Barclays first reported a position in Exact Sciences in Q2 2013 and held it in 51 quarters.
Barclays's Exact Sciences position peaked at $23.7M in Q2 2025.
7 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.